106 mM (4% [w/v]) trehalose dihydrate
Sponsors
Horizon Therapeutics Ireland Designated Activity Company
Conditions
Immunoglobulin G4-related disease (IgG4-RD)Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).
Phase 3
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease.
Active, not recruitingCTIS2023-508290-81-00
Start: 2020-12-18Target: 90Updated: 2025-10-27
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study with Open-Label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults with Myasthenia Gravis [VIB0551.P3.S1 MINT]
Active, not recruitingCTIS2023-510006-40-00
Start: 2021-03-22Target: 125Updated: 2025-12-05